[Current Status and Challenges in the Regulation of Weight Management Medical Devices]

With the global obesity crisis worsening and China launching the "Weight Management Year" initiative, demand for weight management medical devices has grown significantly. This study focuses on two key issues: the lack of a unified global classification framework for such devices and the fragmented understanding of international regulatory differences.

From the technical perspective of medical device classification and determination, this paper reviews the regulatory landscape of such devices in the United States, Europe, Japan, South Korea, Australia, and Canada. Focusing on intragastric balloons, cryolipolysis devices, and medical-grade smart body fat scales, it compares classification approaches, restrictions on claims, and clinical validation requirements, while also analyzing controversies such as vague definitions and inconsistent risk assessments.

The analysis shows notable differences in regulatory philosophies across countries. The United States uses a model centered on risk and efficacy; the European Union emphasizes technical substantiation and full product lifecycle management; Japan and South Korea prioritize adaptability to local populations. A critical problem is the lack of unified core performance parameters: for example, the required fat reduction rate for cryolipolysis devices is ≥20% in the US but ≥15% in the EU, and there are no consistent thresholds for body fat measurement accuracy. This not only creates regulatory ambiguity but also leaves room for regulatory arbitrage. Overall, the global regulatory environment for weight management devices remains uncoordinated, facing challenges from vague definitions and inconsistent standards.

Drawing on international experiences and China's specific regulatory context, this study proposes a framework for a China-specific regulatory system for weight management devices. Core recommendations include: refining technical and clinical standards for key products like medical-grade smart body fat scales; strengthening management of intended use claims to clarify regulatory boundaries; and establishing a closed-loop, full-lifecycle management system integrated with real-world data. These measures are expected to shift China's regulatory model from reactive response to proactive leadership, ultimately contributing to a "Chinese solution" to both high-quality industrial development and global regulatory harmonization.